Clinical Trials & Remyelination
(Cunniffe Group)
Our research mission focusses on preventing and reversing disability in people living with multiple sclerosis. We lead groundbreaking research in the field of remyelination, dedicated to repairing the nervous system and improving the lives of individuals affected by demyelinating disorders. We therefore conduct drug trials of remyelination-promoting drugs, and conduct clinical studies to better understand the reasons people with MS fail to repair the damage done by the disease.
​
Learn more about our trials here and related projects below.
Meet the Group
Learn a little more about each member of the Remyelination group by clicking on their profile picture below.
.png)
Publications
Click the journal covers or paper titles below to view the key publications to which members of the Clinical Trials and Remyelination group have contributed.
​
Visual outcome measures in clinical trials of remyelinating drugs
​
​
Remyelination varies between and within lesions in multiple sclerosis following bexarotene
​
Seeing is believing: Identifying remyelination in the central nervous system
​
Remyelination in humans due to a retinoid-X receptor agonist is age-dependent
​
​
​
Promoting remyelination in multiple sclerosis
​
​
​​
Books
Carpenter’s neurophysiology: a conceptual approach (6th ed.)
​